MBI has been associated with higher Aβ PET uptake in regions that typically exhibit amyloidosis early during the course of AD,35 and significant associations with tau-PET have been observed in regions corresponding to Braak I–III pathological stages.29,36 Convergent findings across fluid and neuroimaging biomarkers underscore the robust associations between MBI and the core AD pathologies. Here, MAPT is linked to amyloidosis.